Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin with Carboplatin and Paclitaxel in Recurrent Ovarian Cancer
NCT02050009Phase 1Withdrawn
- Sponsor
- Fox Chase Cancer Center
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of liquid metformin (Aspargo Labs) in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Fox Chase Cancer Center. Primary endpoint: Probability of successes in patients receiving the combination therapy at 2 years. Status: withdrawn.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02050009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02050009.